

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/127, 9/48, 9/02</b>		A1	(11) International Publication Number: <b>WO 99/11242</b> (43) International Publication Date: <u>11 March 1999</u> (11.03.99)
(21) International Application Number: <u>PCT/US98/18475</u> (22) International Filing Date: <u>4 September 1998 (04.09.98)</u>		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: <u>60/057,819</u> 4 September 1997 (04.09.97) US		Published <i>With international search report.</i>	
(71) Applicant: BIOZONE LABORATORIES, INC. [US/US]; 580 Garcia Avenue, Pittsburgh, CA 94565 (US).			
(72) Inventor: KELLER, Brian, C.; 2507 Brocket Court, Antioch, CA 94509 (US).			
(74) Agents: WISEMAN, Thomas, G. et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).			

102b

(54) Title: ORAL LIPOSOMAL DELIVERY SYSTEM

(57) Abstract

A liposome-capsule dosage unit system for the delivery of a biologically active material is formed by encapsulating a biologically active materials in liposomes and then placing the liposome encapsulated material into a capsule. The capsule is typically a soft gel capsule or a two piece capsule capable of tolerating a certain amount of water. A less water tolerant capsule can be employed if the liposomes are dehydrated prior to placement within the capsule. Biologically active material include drugs, nutritional supplements, vitamins, minerals, enzymes, hormones, proteins and polypeptides. The system is especially suited for the delivery of materials with poor oral solubility, materials that are not absorbed or are poorly absorbed from the gastrointestinal tract, and materials that have conventionally been given by an invasive route. The system can be administered orally, intra-ocularly, intranasally, rectally, or vaginally.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ORAL LIPOSOMAL DELIVERY SYSTEM

### **Background of Invention**

#### Field of Invention:

5        The invention generally relates to the field of liposome based drug delivery systems.

#### Description of Background Art:

10      The therapeutic effect of an administered substance is usually directly related to the quantity and rate at which the substance reaches the bloodstream. There are many factors that affect the ability of the substance to reach the systemic circulation including; the site of entry into the body, the physical form of the substance, the design of the formulation of the product, various physicochemical properties of the compound and the excipients, and control and maintenance of the location of the substance at the proper absorption site.

15      Oral delivery of a therapeutic substance is the most common form of delivery today because of convenience and ease of administration, however, it is not the most reliable route of administration and can often be inefficient and erratic. Factors that influence the absorption, and thus the ability of the substance to reach the bloodstream, of an orally administered substance are related to the physicochemical properties of the substance, the physiologic factors in the gastrointestinal tract and the variables in the dosage form. Conventional oral dosage forms consist of solutions, suspensions, powders, two-piece gelatin capsules, soft gelatin capsules, compressed tablets, and coated tablets. It is generally the case that gastrointestinal absorption is most rapid with solutions and progressively slower as you move toward coated tablets in the above continuum. Liquid dosage forms are generally much faster absorbed than solid forms because dissolution is not a rate determining step in the absorption process.

It has long been the idealized object of drug delivery technology to design a dosage form that optimizes effectiveness, maximizes drug reliability and maximizes safety of the delivered compound. Oral dosage forms began to become optimized in the late 1940's and early 1950's when sustained-release technology appeared on the 5 pharmaceutical scene. The principle benefit of this new type of delivery system was to improve drug performance by increasing the duration of drug action and reducing the dosing interval required to achieve a therapeutic effect. Controlled-drug delivery technology, a new concept for improving drug efficacy was developed in the late 1960's. The principle benefit of this technology is to control the rate of dissolution 10 from the solid dosage form to enhance bioavailability, improve safety, and decrease the dosing interval. Within the last twenty years a newer concept in oral drug delivery technology has been developed and is referred to as a therapeutic system. The essential component of the therapeutic system is the incorporation of advanced 15 engineering controls that release drug from the dosage form at appropriate times in response to stimuli, e.g., preprogrammed wax matrix.

Capsules are a convenient and popular solid dosage form used for drugs, vitamins and nutritional supplements worldwide. The drug substance is enclosed within gelatin walls of the capsule, which can be either a two piece hard shell or a soft shell (also known as the soft elastic capsule). The soft elastic capsule (SEC) is a soft, 20 globular, gelatin shell somewhat thicker than that of hard gelatin capsules. The gelatin is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The greatest advantage of soft gel capsule over two piece gelatin capsules is that soft gels can encapsulate liquids, semiliquids, and pastes due to the manufacturing process which hermetically seals the two halves together. There are several manufacturing 25 processes by which soft gel capsules are made, those include the plate process, the rotary die process, the Norton capsule machine and Accogel, or Stern machine. A newer technology allows a two-piece gelatin capsule to tolerate liquids, semiliquids and pastes by sealing the upper and lower pieces together to prevent leakage of encapsulated material.

Liposomes are microscopic, three-dimensional lipid vesicles, made up of a phospholipid bilayer membrane that surrounds and separate an aqueous compartment. The discovery of liposomes has been credited to Alec Bangham, a British biologist and physician, who first described swollen lipid particles in the early 1960's.

5 (Bangham A., et al, J. Mol Biol., 13, 238, 1965). However there is evidence of the observation of multilamellar liposomes dating back to 1911. (Lasic, D., *Liposomes*, 1993). Two decades after Bangham and his colleagues described their discovery the field of liposome science began to take hold, and the pharmaceutical and pharmacological rational that justifies the use of liposomes as drug carriers was being  
10 put into practice. Today, the medical applications of liposomes range widely from systemic anticancer therapy to enhancing topical anesthesia and gene delivery.

The use of liposomes orally first begin in the mid 1970's. The attributes of phospholipid based liposomes, e.g., well organized structures able to encapsulate a variety of compounds, with an excellent safety profile, were well known at the time.

15 Medical researchers believed that this would be an ideal application to potentially enhance gastrointestinal absorption, protect the encapsulated ingredient from metabolic degradation and perhaps release the encapsulate slowly, thus providing a form of sustained release. Early studies showed that liposome encapsulated drugs were better absorbed than non-liposome encapsulated or "free" drug. In addition to  
20 drug molecules, proteins, peptides and enzymes were delivered orally with liposomes. In an attempt to develop an oral treatment for hemophilia with blood clotting factor VIII, a novel technique was developed which made possible high-yield entrapment of Factor VIII in a liposome. (Gregoridias, G. et al., J. Microencap., 1(1):33-45,1984). Liposomal encapsulated Factor VIII was administered to patients orally and was absorbed from the intestines. (Sakuragawa N., Thrombosis Research 38(6):681-5, 1985). Early enthusiasm with liposome encapsulated insulin showed that small but significant amount of insulin could reach the circulation (Woody, JF, Critical Rev Ther. Drug Carrier Sys. 2(1):1-18, 1985). Significant antibody response was elicited after oral administration of liposome-entrapped snake

- 4 -

venom (enzymes and peptides) compared to no response from free venom. (New, RR, *Toxicon*. 23(2):215-9, 1985).

More recently, feasibility of oral liposomes for a variety of therapeutic uses has been demonstrated. Increased bioavailability of liposomally encapsulated

5 superoxide dismutase (Regnault C., et al, *Biopharm & Drug Disp* 17,165-174, 1996) a potent antioxidant used in the treatment of radiation-induced fibrosis, which is poorly absorbed orally, from 14% (free) to 57% with liposomes with ceramides.

Hypocalcemia was observed 1 h after the administration of liposomes loaded with 1 mg of calcitonin. (Arien a., et al, *Pharm Research* 12(9):1289-1292, 1995). This 10 result was surprising because liposomes were presumed to be unstable against the action of bile salts, however they were able to partially protect the peptide from enzymatic degradation. In another study, recombinant human erythropoietin (Epo), used to treat renal anemia, was encapsulated in liposomes. Bioavailability of oral Epo is poor because it is a protein and broken down in the GI tract by proteolytic enzymes. 15 Absorption and a long pharmacological effect and lag were observed, suggesting that liposomes were trapped in a site before entering the bloodstream, and eliciting a sustained release effect. (Maitani Y., *J Pharm Sc* 85(4):440-445, 1996).

The pharmaceutical related problems associated with administering liposomes orally are: 1) pH of the stomach, 2) bile salts and 3) digestive enzymes, primarily 20 lipases. The unbuffered pH of the stomach can range from 1.5 to 2.5 and causes chemical instability of the liposome membrane surface.

Bile salts act as detergents and cause instability of the liposome bilayer by emulsification. Upon exposure to lipases and other enzymes, the polar head groups or the acyl chains of the phospholipids can be cleaved and thus rupture the liposome 25 vesicle.

#### Description of the Invention

Although certain chemical and stearic modifications can be made to liposomes to help stability, the incorporation of a fluid liposome dispersion into a gelatin based

capsule can improve stability, provide a convenient dosage form, and assist in sustained release characteristics of the liposome. The present invention broadly relates to a novel delivery system for biologically active material whereby the biologically active material is encapsulated into liposomes or formulated as a

5 preliposome formulation and then put into a capsule. The capsule can be a soft gel capsule capable of tolerating a certain amount of water, a two piece capsule capable of tolerating a certain amount of water or a two piece capsule where the liposomes are preformed then dehydrated. Biologically active material in this invention can be, but is not limited to, drugs, nutritional supplements, vitamins, minerals, enzymes,

10 hormones proteins and polypeptides.

The delivery system of the invention is especially suitable for 1) biologically active materials with poor oral solubility, e.g. morphine, acyclovir, propanolol, fluoxetine, 2) newly discovered drugs, proteins and peptides that are not absorbed or are poorly absorbed from the gastrointestinal tract, and 3) drugs, proteins, hormones

15 and nutrients that can not be absorbed from the GI tract and have to be given by an invasive route such as injection or nasal inhalation, e.g. Vitamin B<sub>12</sub>, calcitonin, insulin, erythropoietin, superoxide dismutase.

The liposome-capsule unit containing biologically encapsulated material can be taken in addition to orally, used for topical unit-of-use application, or other routes

20 of application such as intra-ocular, intranasal, rectal, or vaginal.

The liposomes in this invention are comprised of any bilayer forming lipid, which includes phospholipids, sphingolipids, glycosphingolipids, and ceramides. The typical size range of the liposomes is 20 nm-1000 nm. These liposomes can be rehydrated, dehydrated, partially hydrated or fully hydrated. It is also possible to

25 employ a preliposome formulation as the liposome encapsulated biologically active material (liposome-drug complex). This formulation is composed of the biologically active material, phospholipids and cholesterol, and upon contact with water, forms liposomes. The liposomes can be mechanically stabilized using certain phospholipids, e.g. phospholipon 90H, and cholesterol at an optimum molar ratio of

2:1. The optimum ratio is expected to vary with the specific phospholipid selected. This stability can protect the liposome from GI degradation.

Gelatin capsules have a lower tolerance to water on their interior and exterior. The usual water tolerance for a soft gel capsule is 10% on the interior. The 5 concentration of water in a liposome formulation can range from 60-90% water. An essential component of the present invention is the formulation of a liposome with a relatively small amount of water, in the range of 5-10%. By making the liposome in a low aqueous system, the liposome is able to encapsulate the biologically active material and the exposure of water to the inside lining of the capsule is limited. The 10 concentration of water should not exceed that of the tolerance of the capsule for which it is intended. The preferred capsule for this invention is one that can tolerate water in the 15-20% range.

The capsulation of liposomes into a gelatin shell improves the stability of the liposome because it is protected from exposure to the air and thus oxidation. This 15 increases the shelf life of the product. Capsulation will also initially protect the liposome-drug complex from the low pH of the stomach, emulsification from bile salts and degradation of the liposomes *and* the drug substance by digestive enzymes. This protection can be further enhanced when the outer shell of the capsule is coated with a polymer like hydroxyethylmethyl cellulose propylethyl acetate, or 20 hydroxypropylmethylcellulose propylethyl thallate.

In the past, all administration of oral liposomes have been as a liquid, given by intubation directly into the small intestine, to the back of the throat by a gavage 25 syringe or by dropper directly into the mouth. These are very impractical ways of administering therapeutic agents because they can be messy, provide an inaccurate dose, and are difficult for patients to handle. In addition many biologically active ingredients have a bitter, astringent and unpleasant taste that is unpalatable and difficult to mask. Liposomes in a capsule dosage form provide a convenient, easy to manage unit-of-use which can be more easily handled by the patient than the usual liquid form of a liposome preparation. An easy to take dosage form, such as a

- 7 -

capsule, leads to increased compliance by the patient. Noncompliance is disturbingly common. Over one-half of the 1.6 billion prescriptions written annually in the U.S. are taken incorrectly, and 30-50% of the prescribed medications fail to produce their intended results. The economic consequences of medication noncompliance is in 5 excess of \$100 billion annually. A significant barrier to compliance is regimen complexity. Reduction of regimen complexity includes use of convenient dosing formulations. It is estimated that 50% of the American population don't like taking oral liquids. By administering a liposome in a capsule, certain compliance issues are overcome. There has been very little discussion or development of an oral dosage 10 form for liposomes up until now and there are no commercial oral liposome dosage forms available.

The gel caps best used for this invention range in size and shape. The various shapes include, but are not limited to, oval, oblong, cylindrical, round and torpedo shaped. Size of soft elastic capsules is measured by the amount of liquid that can fit 15 into the capsule. The size range of soft gel capsules in this invention is 0.045 cc (0.75 minim) to 5 cc (81.2 minim). The typical size range of two piece capsules is from 600 mg to 30 mg; these capsules are numbered from 000, the largest, to 5, the smallest.

## EXAMPLES

Example 1

Vitamin B <sub>12</sub> LipoCap Formulation	
Ingredient	Concentration (%)
Purified water, USP	10
Cyanocobalamin, USP	0.345
Phospholipon 90H (DPPC)	3
Cholesterol, NP	2
Vitamin E, USP	1
Benzyl Alcohol, NF	1
Propylene glycol, USP	82.655

5 Components are commingled and liposomes are made using the injection method (Lasic, D., *Liposomes*, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting capsule contains 2500 mcg of Vitamin B<sub>12</sub>. Large scale manufacturing methods for filling gel caps, 10 such as the rotary die process, are the preferred method for commercial applications.

Example 2

Co-Enzyme Q <sub>10</sub> LipoCap Formulation	
Ingredient	Concentration
Purified water, USP	5
Phospholipon 90H (DPPC)	5
Cholesterol, NF	3
Vitamin E, USP	1
CoQ <sub>10</sub>	1.29
Potassium Sorbate, NF	1
Propylene glycol, USP	84.46

Components are commingled and liposomes are made using the injection 15 method (Lasic, D., *Liposomes*, Elsevier, 88-90, 1993). When liposome mixture

cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting capsule contains 10 mg CoQ10. Filling of gel caps on a large scale is best with the rotary die method or others such as the Norton capsule machine.

5

Example 3

Vitamin E LipoCap Formulation	
Ingredient	Concentration (%)
Sorbitan Oleate	2.0
Vitamin E, USP	89.8
Purified Water	4.0
Potassium Sorbate	0.2
Polysorbate 20	2.0
Phospholipon 90 (DPPC)	2.0

Components are commingled and liposomes are made using the injection method (Lasic, D., *Liposomes*, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting one gram capsule contains 898 IU of Vitamin E. Large scale manufacturing methods for filling gel caps, such as the rotary die process, are the preferred method for commercial applications.

- 10 -

Example 4

<b>L-Carnitine LipoCap Formulation</b>	
<b>Ingredient</b>	<b>Concentration</b>
Propylene Glycol	3.0
Lycosin-75 <sup>R</sup> (Roquette)	73.5
L-Carnitine	20.0
Phospholipon 80H (DPPC)	3.5

5 Components are commingled and liposomes are made using the injection method (Lasic, D., *Liposomes*, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting one gram capsule contains 735 mg of L-Carnitine. Filling of gel caps on a large scale is best  
10 with the rotary die method or others such as the Norton capsule machine.

Claims

1. A liposome - capsule dosage unit comprising liposomes containing a  
5 biologically active material enclosed within a capsule.

2. The liposomes are comprised of any bilayer forming lipid including  
phospholipids, sphingolipids, glycosphingolipids, and ceramides.

10 3. The liposome - capsule dosage unit of claim 1 wherein the biologically  
active material is selected from the group consisting of drugs, nutritional supplements,  
vitamins, minerals, enzymes, hormones, proteins and peptides.

15 4. The liposome - capsule dosage unit of claim 1 prepared by  
incorporating a preliposome formulation containing the biologically active material or  
a biologically active material encapsulated within liposomes into the capsule.

20 5. The liposome - capsule dosage unit of claims 1 wherein the  
biologically active material is CoQ<sub>10</sub>.

6. The liposome - capsule dosage unit of claim 1 wherein the biologically  
active material is vitamin B<sub>12</sub>.

7. The liposome - capsule dosage unit of claim 1 wherein the biologically  
25 active material is vitamin E.

8. The liposome - capsule dosage unit of claim 1 wherein the biologically  
active material is L-Carnitine.

- 12 -

9. The liposome - capsule dosage unit of claim 1 wherein the capsule is a soft gel capsule.

10. The liposome - capsule dosage unit of claim 9 wherein the capsule is  
5 tolerant of water.

11. The liposome - capsule dosage unit of claim 10 wherein the water-  
tolerant capsule is composed of two pieces.

10 12. A method of administering a biologically active material comprising  
introducing the liposome - capsule dosage unit of claim 1 to the subject.

13. The method of claim 12 wherein the dosage unit is introduced orally.

15 14. The method of claim 12 wherein the dosage unit is applied topically.

15. The method of claim 12 wherein the unit dosage is introduced  
intraocularly.

20 16. The method of claim 12 wherein the unit dosage is introduced  
intranasally.

17. The method of claim 12 wherein the unit dosage is introduced  
intrarectally.

25 18. The method of claim 12 wherein the unit dosage is introduced  
vaginally.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/18475

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/127, 9/48, 9/02  
 US CL :424/450, 451, 427, 430, 434, 435, 436.  
 According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/450, 451, 427, 430, 434, 435, 436.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS:

search terms: liposomes and capsules

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 4,900,556 A (WHEATLEY et al) 13 February 1990, abstract, Figure 4, and columns 4-10.	1-4, 9, 10, 12 & 13 _____ 5-8 & 14-18
X — Y	US 5,004,611 A (LEIGH) 02 APRIL 1991, abstract, column 3, lines 28-41, column 5, lines 30-68, column 6, line 66 through column 7, line 20 and claims 15-21.	1-4, 10, 12 & 13 _____ 5-9, 11 and 14-18
X — Y	US 4,348,384 A (HORIKOSHI et al) 07 SEPTEMBER 1982, abstract, columns 1-3, examples and claims.	1-4 & 9-13 _____ 5-8

Further documents are listed in the continuation of Box C.  See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• "A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• "B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	"Z"	document member of the same patent family
• "O" document referring to an oral disclosure, use, exhibition or other means		
• "P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
10 NOVEMBER 1998	21 DEC 1998

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer GOLLAMUDI S KISHORE Telephone No. (703) 308-1235
-------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------